Back to top

BioMarin price target raised to $86 from $80 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on BioMarin (BMRN) to $86 from $80 and keeps a Buy rating on the shares. BioMarin’s Q2 w...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)